<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_New_York_City_Description skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:New York City/Description</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="igem_2018_team_content"><DIV class="igem_2018_team_column_wrapper"><DIV class="container"><NAV class="sticky-top py-3 navbar navbar-expand-lg navbar-light mr-auto"><DIV class="container d-flex flex-column flex-md-row justify-content-between"><DIV class="navbar-brand"><A href="https://2018.igem.org/Team:New_York_City">New York City iGEM</A></DIV><DIV class="collapse navbar-collapse" id="navbarSupportedContent"><UL class="navbar-nav mr-auto"><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle py-2 d-none d-md-inline-block" href="#" id="navbarPR" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                                Project
                            </A><DIV class="dropdown-menu" aria-labelledby="navbarPR"><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/HD">What is
                                    Huntington's?</A><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Description">Description</A><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Design">Design</A><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Model">Model</A><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/InterLab">InterLab</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle py-2 d-none d-md-inline-block" href="#" id="navbarNB" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                                Notebook
                            </A><DIV class="dropdown-menu" aria-labelledby="navbarNB"><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Notebook">Notebook</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle py-2 d-none d-md-inline-block" href="#" id="navbarHP" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                                Human Practices
                            </A><DIV class="dropdown-menu" aria-labelledby="navbarHP"><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Human_Practices">Human
                                    Practices</A><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Integrated_Practices">Integrated
                                    Practices</A><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Public_Engagement">Public
                                    Engagement</A><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Collaborations">Collaborations</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle py-2 d-none d-md-inline-block" href="#" id="navbarT" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                                Team
                            </A><DIV class="dropdown-menu" aria-labelledby="navbarT"><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Team">Team</A><A class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Attributions">Attributions</A></DIV></LI></UL></DIV></DIV></NAV></DIV><DIV class="container py-0 align-middle"><H2 align="center">Our Motivation</H2></DIV><DIV class="container"><P class="lead">Huntington's Disease (HD) is an autosomal dominant genetic disorder, meaning that if one allele out
        of two carries the HTT mutation the HD gene will produce the faulty protein of Huntingtin. Therefore, the
        children of an individual suffering from HD will have a 50/50 chance of carrying the faulty gene if they do
        not express it themselves. According to the Huntington's Disease Society of America, the &quot;quintessential family
        disease&quot; and the ability of this disease to wreak such devastating and overarching damage on an individual and
        all those around them are one of the root reasons our team has chosen to tackle HD. For instance, HD is
        adult-onset (30s to 50s) and many individuals go about their lives and form families without the knowledge of
        the storm looming on the horizon. At the time of their diagnosis, their children will be revealed to be at risk
        of inheriting the disease. HD robs a patient of their life, eventually leaving them physically, cognitively, and
        behaviorally inept to continue their daily tasks and responsibilities. Although HD is classified as a rare
        disorder, the tragic and frightful effects it has upon patients, carriers, and families call for a resolution
        to be developed in the near future.</P></DIV><DIV class="container py-0 align-middle"><H2 align="center">Abstract</H2></DIV><DIV class="container"><P class="lead">Huntington's Disease (HD) is an autosomal dominant disorder that leads to the progressive
        degeneration of neurons in the brain, which currently has no cure. HD is typically adult-onset and is
        characterized by a variety of symptoms including memory loss, involuntary movements, poor coordination,
        and impaired decision-making. Mutation in the huntingtin (HTT) gene causes HD, specifically a trinucleotide
        repeat of CAG that is abnormally repeated over 40 times. The goal of our project was to test the effectiveness
        of the plasmid that we generated last year, which targets and blocks endogenous faulty mRNA and releases a
        corrected RNA strand for proper protein synthesis of the HTT gene. The efficacy of this plasmid was tested
        on huntingtin cell lines, specifically the HeLa/polyQ-mCFP cell line. The effectiveness of this treatment was
        tested by evaluating whether the quantity of mutated HTT protein decreases after transfecting cells with the
        engineered plasmid.</P></DIV><DIV class="container"><P class="lead">Sources:</P><OL><LI><A href="https://ghr.nlm.nih.gov/condition/huntington-disease#synonyms">ghr.nlm.nih.gov</A></LI><LI><A href="https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Huntingtons-Disease-Hope-Through#3137_14">ninds.nih.gov</A></LI><LI><A href="http://hdsa.org/what-is-hd/">hdsa.org</A></LI></OL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>